An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

por Fu, Weihui, Liu, Yan, Liu, Li, Hu, Huiliang, Cheng, Xiaobo, Liu, Ping, Song, Zhigang, Zha, Lijun, Bai, Shimeng, Xu, Tingting, Yuan, Songhua, Lu, Fengru, Shang, Zhiying, Zhao, Yihong, Wang, Jing, Zhao, Jun, Ding, Longfei, Chen, Jun, Zhang, Lin, Zhu, Tongyu, Zhang, Xiaoyan, Lu, Hongzhou, Xu, Jianqing
Publicado en EClinicalMedicine (2020)